Nuklearmedizin 2022; 61(02): 192
DOI: 10.1055/s-0042-1746102
Abstracts | NuklearMedizin 2022
WIS-Poster
Radionuklidbatterie/Theranostics

Prognostic value of the De Ritis ratio in patients with NET undergoing retreatment with Lutetium-177-DOTATOC-PRRT

M. Galler
1   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Nuklearmedizin, Berlin
,
J. Rogasch
1   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Nuklearmedizin, Berlin
,
C. Wetz
1   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Nuklearmedizin, Berlin
,
U. Fehrenbach
2   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Radiologie, Berlin
,
C.A. Kunze
3   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institut für Pathologie, Berlin
,
K. Plehm
4   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin
,
H. Jann
4   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin
,
H. Amthauer
1   Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Nuklearmedizin, Berlin
› Author Affiliations
› Further Information
Also available at
 

Ziel/Aim Retreatment with Lutetium-177-DOTATOC/DOTATATE-PRRT has shown a potential benefit in patients who have progressed after initial therapy cycles with a safety profile similar to the initial treatment1. This is to evaluate the De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) and progression-free survival (PFS) after initial PRRT as predictors of the PFS following retreatment.

Methodik/Methods Retrospective, monocentric analysis in 32 patients (median age: 66 [range, 32-81] years) with NET (GEP=22, CUP=8, kidney=1, lung=1) and progression after initial PRRT undergoing retreatment with Lutetium-177-DOTATOC PRRT. AST and ALT were measured one day before retreatment. PFS was defined as the time from treatment/retreatment start until tumor progression according to RECIST 1.1 criteria or death. The prognostic values of the initial PFS and the De Ritis ratio regarding PFS following retreatment was analyzed with univariable and bivariable Cox regression.[1]

Ergebnisse/Results Median PFS after initial PRRT was 31 [9-75] months. Retreatment was performed with a median of 2 [1-3] cycles (median activity per cycle: 6.0 [4.0-7.6] GBq). Progression after retreatment was observed in 28 of 32 patients with median PFS of 11.8 months (95% confidence interval [CI], 7.3-16.3 months). Higher De Ritis ratio was associated with a shorter PFS after retreatment (Hazard ratio [HR]: 3.3, 95%-CI: 1.3-8.9; p=0.016). The initial PFS did not predict the PFS following retreatment ([HR]: 0.99, 95%-CI: 0.97-1.00; p=0.27). Bivariable Cox regression resulted in an HR of 3.4 (p=0.015) for the De Ritis Ratio and 0.99 (p=0.24) for the initial PFS.

Schlussfolgerungen/Conclusions The De Ritis ratio is simple to obtain and could help in identifying patients with NET at high risk of early disease progression after retreatment with PRRT.



Publication History

Article published online:
14 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur/References

  • 1 Strosberg J., Leeuwenkamp O., Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis Cancer Treatment Reviews. 2021 93.
    PubMedSearch in Google Scholar